H.C. Wainwright Keeps Their Buy Rating on Sensus Healthcare Inc (SRTS)


H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Sensus Healthcare Inc (SRTS) today and set a price target of $9. The company’s shares closed on Friday at $5.38, close to its 52-week low of $5.31.

Selvaraju noted:

“Our price target is derived from an EV-to-sales multiple of 6.0x and TTM revenue ($1.57/share). Risks include, but are not limited to: (1) failure of SRT and IORT systems to achieve commercial success due to reimbursement, penetration rate, and/or competition; (2) failure of other potential pipeline products; and (3) potential dilution risk. Sensus Healthcare, Inc. May 13, 2019 H.C. WAINWRIGHT & CO.”

According to TipRanks.com, Selvaraju is a 2-star analyst with an average return of 0.2% and a 36.7% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Bausch Health Companies Inc.

Currently, the analyst consensus on Sensus Healthcare Inc is a Moderate Buy with an average price target of $10.50, implying a 95.2% upside from current levels. In a report issued on May 10, B.Riley FBR also reiterated a Buy rating on the stock with a $14 price target.

See today’s analyst top recommended stocks >>

Based on Sensus Healthcare Inc’s latest earnings release for the quarter ending December 31, the company reported a quarterly net profit of $101.9K. In comparison, last year the company had a GAAP net loss of $1.13 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Sensus Healthcare, Inc. engages in the design, manufacture, and marketing of proprietary medical devices specializing in the treatment of non-melanoma skin cancers and other skin conditions. Its main product is SRT-100, a photon x-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating basal cell and squamous cell skin cancers and other skin conditions such as keloids. The company was founded by Joseph C. Sardano, Richard Golin, Kalman Fishman and Stephen Cohen on May 7, 2010 and is headquartered in Boca Raton, FL.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts